Taming glioblastoma: Targeting angiogenesis

Journal of Clinical Oncology

Volumn 25, Issue 30, 2007, Pages 4705-4706

  Wong, Eric T ^a   Brem, Steven ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUORO 2 METHYL 5 INDOLYLOXY) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY]QUINAZOLINE; 5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; COMBRETASTATIN A4 PHOSPHATE; CYTARABINE; FLUORODEOXYGLUCOSE F 18; GADOLINIUM; IRINOTECAN; N ACETYLCOLCHINOL PHOSPHATE; TIOXAMAST; VASCULOTROPIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; MONOCLONAL ANTIBODY;

ANGIOGENESIS; BLOOD VESSEL PERMEABILITY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DISEASE FREE SURVIVAL; DRUG HALF LIFE; EDITORIAL; GLIOBLASTOMA; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN TARGETING; STANDARD; TISSUE OXYGENATION; NEOVASCULARIZATION (PATHOLOGY); NOTE; PROGNOSIS; SURVIVAL RATE; TUMOR RECURRENCE; VASCULARIZATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; GLIOBLASTOMA; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; SURVIVAL RATE;

EID: 36049007790     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.13.1037     Document Type: Editorial

References (26)

1. Folkman J: Tumor angiogenesis: Therapeutic implications. N Engl J Med 285:1182-1186, 1971
2. Brem S, Cotran R, Folkman J: Tumor angiogenesis: A quantitative method of histological grading. J Natl Cancer Inst 48:347-356, 1972
3. Senger DR, Galli SJ, Dvorak AM, et al: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219:983-985, 1983
4. Vredenburgh JJ, Desjardins A, Herndon JE, et al: Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722-4729, 2007
5. Wong ET, Hess KR, Gleason MJ, et al: Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17:2572-2578, 1999
6. 18F] fluorothymidine positron emission tomography: A pilot study. J Clin Oncol 25:4714-4721, 2007
7. Hess KR, Wong ET, Jaeckle KA, et al: Response and progression in recurrent malignant glioma. Neuro-Oncology 1:282-288, 1999
8. Jain RK: Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med 7:987-989, 2001
9. Winkler F, Kozin SV, Tong RT, et al: Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6:553-563, 2004
10. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal carcinoma. N Engl J Med 350:2335-2342, 2004
11. Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550, 2006
12. Miller KD, Chap LI, Holmes FA, et al: Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23:792-799, 2005
13. Batchelor TT, Sorensen AG, di Tomaso E, et al: AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83-95, 2007
14. Wachsberger PR, Burd R, Marero N, et al: Effect of the tumor vasculardamaging agent, ZD6126, on the radioresponse of U87 glioblastoma. Clin Cancer Res 11:835-842, 2005
15. Siemann DW, Mercer E, Lepler S, Rojiani AM: Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer 99:1-6, 2002
16. Macdonald DR, Casino TL, Schold SC Jr, et al: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280, 1990
17. 18F-FDG. J Nucl Med 46:945-952, 2005
18. Miwa K, Shinoda J, Yano H, et al: Discrepancy between lesion distributions on methionine PET and MR images in patients with glioblastoma multiforme: Insight from a PET and MR fusion image study. J Neurol Neurosurg Psychiatry 75:1457-1462, 2004
19. Olivero WC, Dulebohn SC, Lister JR: The use of PET in evaluating patients with primary brain tumours: Is it useful? J Neurol Neurosurg Psychiatry 58:250-252, 1995
20. Ruff RL, Posner JB: Incidence and treatment of peripheral venous thrombosis in patients with gliomas. Ann Neurol 13:334-336, 1983
21. Quevedo JF, Buckner JC, Schmidt JL, et al: Thromboembolism in patients with high-grade glioma. Mayo Clin Proc 69:329-332, 1994
22. Ozcan C, Wong SJ, Hari P: Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 354:980-982, 2006
23. Allen JA, Adlakha A, Bergethon PR: Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. Arch Neurol 63:1475-1478, 2006
24. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100:57-70, 2000
25. Wong ET: Tumor growth, invasion, and angiogenesis in malignant gliomas. J Neurooncol 77:295-296, 2006
26. Sakariassen PØ, Prestegarden L, Wang J, et al: Angiogenesis-independent tumor growth mediated by stem-like cancer cells. Proc Natl Acad Sci U S A 103:16466-16471, 2006